Inflection Biosciences Ltd

Dublin, Ireland, November 26, 2020 - Inflection Biosciences is pleased to announce that its first-in-class dual PIM/PI3K porgram was awarded a Seal of Excellence by the European Commission. The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020. Projects which were judged to deserve funding but did not get it due to budget limits receive the Seal of Excellence. It recognises the value of the proposal and helps other investors take advantage of the Horizon 2020 evaluation process. 

Dublin, Ireland, July 30, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced the publication of pre-clinical data showing that the company’s first-in-class PIM/PI3K inhibitor, IBL-202, has promise as a treatment for diffuse large B-cell lymphoma (DLBCL). This research has recently been published in the peer reviewed Journal Leukaemia & Lymphoma. The publication titled ‘Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma’ can be accessed here.

The publication is the result of a collaboration with Dr. Giles Best of the Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Australia, and member of the CLL Australian Research Consortium (CLLARC), Sydney, Australia.

Dr. Best, the lead author on the publication, commented: “The combination of IBL-202 and venetoclax was highly synergistic against DLBCL cells, which may permit the utilization of lower drug concentrations and mitigate against adverse effects.”

DLBCL is the most common type of non-Hodgkin lymphoma (NHL) worldwide with a global incidence of over 150,000. It is considered an aggressive lymphoma and 30-40% of patients fail standard chemoimmunotherapy due to underlying biological heterogeneity.

The BCL-2 inhibitor, venetoclax, has proven to be highly effective in the treatment of chronic lymphocytic leukaemia (CLL) but has limited effects in DLBCL. A major determinant of this resistance is up-regulation and co-expression of MCL-1 and compensatory activation of pro-survival signalling via the PI3K-AKT pathway following venetoclax exposure. All four PI3-kinase isoforms are involved in different stages of malignancy, suggesting signalling via alternate isoforms may compensate in cells treated with selective PI3K inhibitors, resulting in drug-resistance. PIM kinase has been shown to be highly expressed in DLBCL, correlating with poor prognosis. PIM kinase is one of the drivers of dysregulated PI3-kinase signalling. Therefore, the combination of venetoclax with inhibition of the PIM and PI3-kinases, may be beneficial in DLBCL.

These published results show that IBL-202 simultaneously suppresses interacting signalling pathways, which down-regulate MCL-1, contributing to the synergy of IBL-202 with the BCL-2 inhibitor and abrogates the proliferation and survival of DLBCL cells. This work builds on previously published data showing that IBL‐202 may be an effective strategy for targeting CLL cells alone and in combination with venetoclax.

About Inflection Biosciences

Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. The company's pipeline was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML and multiple myeloma. The IBL-100 series comprises selective pan-PIM kinase inhibitors. The partnered pipeline comprises AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. For more information please visit www.inflectionbio.com

For Further Information Contact:

Inflection Biosciences Ltd

Darren Cunningham, Chief Executive Officer

E: dcunningham@inflectionbio.com

T: +353 (0)1 4003615

Darren Cunningham, CEO Inflection Biosciences, spoke with Christine Corrado from Proactive Investors about the potential for its first-in-class IBL-202 program for CLL and other B-cell malignancies.

Dublin, Ireland, February 19th, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of Shaun McNulty, Ph.D., as its Chief Scientific Officer. Dr. McNulty was most recently Chief Scientific Officer at Biosceptre and brings over 25 years of industry experience to Inflection Biosciences.

Dr. McNulty commented “I am delighted to join Inflection Biosciences and look forward to progressing its portfolio of candidates into the clinic. Inflection Biosciences’ approach exploits key interactions between PIM and PI3 kinase pathways. It has been shown that combined inhibition of both pathways by first-in-class IBL-202 may prevent the development of resistance observed for existing PI3 kinase inhibitors, and has the potential to deliver a new treatment option for cancer patients with significant unmet medical needs.”

Darren Cunningham, CEO of Inflection Biosciences, added “Shaun’s appointment comes at an exciting time for Inflection Biosciences as we position our programs for clinical development. His proven track record of successfully progressing candidates from pre-clinical into clinical development make him a great fit and well placed to help us accelerate our development plans.”

Dr. Shaun McNulty is an experienced Chief Scientific Officer, with over 25 years of experience in the biotechnology and pharmaceutical sectors. Having obtained his doctorate in kinase-mediated signalling in glioma cells, from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge, researching kinase-modulated signalling, transcription factor activation and protein expression. Shaun then held drug discovery leadership positions of increasing seniority for Pfizer and GSK, managing small molecule programmes into preclinical development and validating kinases as therapeutic targets. He worked on the Lyrica and Neurontin drug programmes and published more than thirty papers characterising signalling pathways.

Shaun moved into the Biotechnology sector in 2006, joining Syntaxin to direct their oncology discovery portfolio. He then moved to ImmBio, directing scientific collaborations and developing a fundraising strategy. As Biosceptre’s CSO since 2014, Shaun directed a portfolio of oncology candidates, obtaining regulatory approval for two candidates to enter the clinic. He is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com

For Further Information Contact:

Inflection Biosciences Ltd

Darren Cunningham, Chief Executive Officer

E: dcunningham@inflectionbio.com

T: +353 (0)1 4003615